Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?

Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 2 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.

Integral Molecular Enables Membrane Protein Antibody Discovery

With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.

INDUSTRY EXPERIENCE

With 15+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.

Proven Quality

Integral Molecular’s technologies have contributed to scientific discoveries featured in 70+ peer-reviewed publications.

Open Communication

Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.

Membrane Protein Solutions

LEARN MORE

MPS Antibody Discovery

 Integral Molecular harnesses a full suite of Membrane Protein Solutions to deliver lead MAbs.
LEARN MORE

Lipoparticles

 Lipoparticles are virus-like particles that concentrate membrane proteins in their native-conformation for better immunization and screening.
LEARN MORE

Epitope Mapping

 Detailed epitope mapping informs antibody mechanism of action and strengthens intellectual property.
LEARN MORE

Membrane Proteome Array

 The Membrane Proteome Array utilizes 5,300 human membrane proteins to profile MAb specificity and evaluate off-target safety.
LEARN MORE

Vaccine Development

 Integral Molecular offers innovative tools including Reporter Virus Technology for faster characterization of immune responses.
LEARN MORE

Therapeutic Pipeline

 We offer licensing opportunities for therapeutic antibodies against untapped targets.

70+ Publications Including Cell, Science & Nature

VIEW ALL PUBLICATIONS

Trusted by 100+ Companies

Ready to Get Started?

We have worked with more than 100 top biotech and pharmaceutical companies to help them succeed. Let's talk about how we can help you.
GET STARTED
Or call (215) 966-6061